Brand 'Evergreening' Piques FDA Interest, But Solutions Remain Elusive

Agency eager to hear suggestions on the subject, also known as product hopping, but even reform advocates were cautious of stifling meaningful reformulations of products.

Box fighters trainning outdoor . Mixed media

A chorus of industry stakeholders is pleading with the US FDA to prevent innovators from employing anticompetitive evergreening strategies, but the agency seems unlikely broach the subject in the near future, as action could involve a double-edged sword.

FDA panelists demonstrated serious interest at the agency's July 18 Hatch-Waxman public meeting on how to approach evergreening, which involves...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics